StocksFundsScreenerSectorsWatchlists
GKOS

GKOS - Glaukos Corp Stock Price, Fair Value and News

98.18USD-1.08 (-1.09%)Market Closed

Market Summary

GKOS
USD98.18-1.08
Market Closed
-1.09%

GKOS Alerts

  • 4 major insider sales recently.

GKOS Stock Price

View Fullscreen

GKOS RSI Chart

GKOS Valuation

Market Cap

4.9B

Price/Earnings (Trailing)

-36.45

Price/Sales (Trailing)

15.6

EV/EBITDA

-43.26

Price/Free Cashflow

-62.95

GKOS Price/Sales (Trailing)

GKOS Profitability

EBT Margin

-42.49%

Return on Equity

-29.17%

Return on Assets

-14.32%

Free Cashflow Yield

-1.59%

GKOS Fundamentals

GKOS Revenue

Revenue (TTM)

314.7M

Rev. Growth (Yr)

15.64%

Rev. Growth (Qtr)

5.53%

GKOS Earnings

Earnings (TTM)

-134.7M

Earnings Growth (Yr)

-17.03%

Earnings Growth (Qtr)

-20.94%

Breaking Down GKOS Revenue

Last 7 days

5.5%

Last 30 days

14.1%

Last 90 days

12.2%

Trailing 12 Months

106.6%

How does GKOS drawdown profile look like?

GKOS Financial Health

Current Ratio

5.34

Debt/Equity

0

Debt/Cashflow

-75.56

GKOS Investor Care

Shares Dilution (1Y)

3.33%

Diluted EPS (TTM)

-2.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023289.1M296.8M303.6M314.7M
2022293.7M288.3M284.9M282.9M
2021237.6M284.1M294.0M294.0M
2020238.3M211.3M217.6M225.0M
2019195.2M210.6M225.2M237.0M
2018163.5M165.4M168.9M181.3M
2017127.2M139.9M150.8M159.3M
201680.1M90.9M101.5M114.4M
201552.0M58.7M65.5M71.7M
201427.1M33.3M39.4M45.6M
201300020.9M

Tracking the Latest Insider Buys and Sells of Glaukos Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 08, 2024
thurman alex r.
sold
-137,944
100
-1,372
svp & chief financial officer
Apr 08, 2024
gilliam joseph e
acquired
2,493,100
41.69
59,801
president & coo
Apr 08, 2024
gilliam joseph e
sold
-6,008,360
100
-59,801
president & coo
Apr 05, 2024
thurman alex r.
sold
-25,316
96.6269
-262
svp & chief financial officer
Apr 05, 2024
gilliam joseph e
acquired
135,577
55.18
2,457
president & coo
Apr 05, 2024
gilliam joseph e
sold
-237,862
96.81
-2,457
president & coo
Apr 04, 2024
gilliam joseph e
acquired
11,036
55.18
200
president & coo
Apr 04, 2024
thurman alex r.
sold
-41,371
95.3253
-434
svp & chief financial officer
Apr 04, 2024
gilliam joseph e
sold
-19,314
96.57
-200
president & coo
Apr 03, 2024
gilliam joseph e
acquired
11,036
55.18
200
president & coo

1–10 of 50

Which funds bought or sold GKOS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
Banque Cantonale Vaudoise
sold off
-100
-276,000
-
-%
Apr 10, 2024
Yarbrough Capital, LLC
unchanged
-
69,974
445,803
0.02%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
unchanged
-
710
4,526
-%
Apr 05, 2024
GAMMA Investing LLC
added
1.29
4,515
66,569
0.01%
Apr 05, 2024
CWM, LLC
reduced
-35.6
-16,000
52,000
-%
Apr 03, 2024
Versant Capital Management, Inc
reduced
-14.63
123
9,900
-%
Mar 27, 2024
NOMURA HOLDINGS INC
added
3.18
1,521,560
18,444,400
0.04%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-4.56
2,730
334,733
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
new
-
2,543,680
2,543,680
0.01%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-0.06
21,957,000
416,268,000
0.01%

1–10 of 42

Are Funds Buying or Selling GKOS?

Are funds buying GKOS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GKOS
No. of Funds

Unveiling Glaukos Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
brown capital management llc
5.53%
2,697,794
SC 13G/A
Feb 13, 2024
burns thomas william
5.08%
2,552,501
SC 13G/A
Feb 13, 2024
vanguard group inc
10.73%
5,236,738
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 22, 2024
blackrock inc.
16.2%
7,894,315
SC 13G/A
Jan 10, 2024
wellington management group llp
2.75%
1,340,500
SC 13G/A
Dec 11, 2023
fmr llc
-
0
SC 13G
Feb 14, 2023
burns thomas william
5.71%
2,807,641
SC 13G/A
Feb 14, 2023
brown capital management llc
5.69%
2,712,809
SC 13G/A
Feb 09, 2023
vanguard group inc
11.21%
5,349,225
SC 13G/A

Recent SEC filings of Glaukos Corp

View All Filings
Date Filed Form Type Document
Apr 10, 2024
4
Insider Trading
Apr 09, 2024
4
Insider Trading
Apr 09, 2024
4
Insider Trading
Apr 08, 2024
144
Notice of Insider Sale Intent
Apr 08, 2024
144
Notice of Insider Sale Intent
Apr 05, 2024
144
Notice of Insider Sale Intent
Apr 05, 2024
144
Notice of Insider Sale Intent
Apr 05, 2024
4
Insider Trading
Apr 05, 2024
4
Insider Trading
Apr 04, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Glaukos Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
193.3B
40.1B
-7.74% 9.17%
33.78
4.82
-8.12% -17.45%
69.5B
19.5B
1.13% -5.26%
55.32
3.56
4.02% -22.04%
24.4B
3.9B
4.50% -2.28%
54.79
6.31
3.42% 23.09%
21.4B
14.8B
-1.84% -1.34%
8.05
1.44
2.12% 209.17%
MID-CAP
9.2B
12.3B
-3.51% -12.61%
22.18
0.75
-2.44% -22.68%
9.2B
3.5B
-2.27% 17.56%
32.29
2.63
4.97% 18.89%
9.1B
2.7B
-7.47% -34.56%
-14.3
3.41
-4.68% 82.43%
6.6B
4.0B
-4.70% -20.93%
-49.38
1.68
1.10% 85.84%
3.5B
366.4M
0.09% 23.27%
-569.11
9.43
33.86% 89.83%
2.3B
6.6B
-4.53% -3.52%
11.91
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
-7.20% -16.80%
-1.97
0.42
7.73% -1066.14%
380.3M
166.7M
-0.70% -5.95%
-4.6
2.28
6.67% -456.34%
272.4M
324.0M
24.04% -26.14%
-1.42
0.84
-3.19% -337.41%
53.7M
52.3M
-9.88% -51.41%
-2.87
1.03
17.61% 19.28%
4.1M
3.7M
-7.69% 310.53%
-0.33
1.09
5.77% 8.23%

Glaukos Corp News

Latest updates
Defense World14 hours ago
Defense World10 Apr 202409:16 am
MarketBeat10 Apr 202401:17 am
Yahoo Finance08 Apr 202402:41 pm
Seeking Alpha03 Apr 202404:35 pm

Glaukos Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue5.5%82,365,00078,048,00080,399,00073,899,00071,227,00071,269,00072,685,00067,681,00073,240,00074,710,00078,093,00067,968,00073,234,00064,831,00031,558,00055,336,00065,849,00058,509,00058,600,00054,026,00054,076,000
Gross Profit6.6%63,474,00059,538,00060,296,00055,828,00054,005,00054,408,00054,852,00050,618,00056,375,00059,340,00060,334,00051,335,00053,644,00046,899,0009,890,00022,807,00049,945,00050,806,00050,730,00046,915,00046,958,000
Operating Expenses16.6%102,096,00087,548,00089,371,00088,821,00087,739,00076,019,00091,612,00040,826,00074,244,00048,316,00074,556,00063,140,00065,036,00059,251,00057,087,00075,419,00079,642,00063,221,00056,970,00048,855,00045,061,000
  S&GA Expenses16.2%63,034,00054,247,00053,137,00053,650,00051,927,00047,149,00049,900,00043,949,00047,566,00044,470,00045,300,00041,921,00043,792,00038,947,00038,116,00050,546,00059,611,00044,443,00037,656,00034,925,00032,104,000
  R&D Expenses--------26,877,000---21,219,000-------13,930,00012,957,000
EBITDA Margin-1.2%-0.35-0.35-0.35-0.41-0.28-0.24-0.13-0.03-0.11-0.08-0.16-0.32---------
Interest Expenses0.9%3,428,0003,398,0003,399,0003,408,0003,409,0003,481,0003,414,0003,416,0003,424,0003,413,0003,306,0003,229,000---------
Income Taxes113.5%79,00037,000400,000400,000298,000247,000-105,000300,000-363,000202,000208,000279,000-3,243,000-889,000-7,384,000-450,000-65,841,000187,00072,000122,000530,000
Earnings Before Taxes-20.8%-36,718,000-30,407,000-32,377,000-34,225,000-31,162,000-27,329,000-45,641,0005,703,000-22,235,0006,432,000-17,274,000-16,190,000-13,891,000-16,637,000-47,278,000-54,508,000-29,260,000-13,319,000-6,237,000-1,220,0002,309,000
EBT Margin-0.6%-0.42-0.42-0.42-0.48-0.35-0.31-0.19-0.09-0.17-0.14-0.23-0.40---------
Net Income-20.9%-36,818,000-30,444,000-32,812,000-34,626,000-31,460,000-27,576,000-45,536,0005,377,000-21,872,0006,230,000-17,482,000-16,469,000-10,648,000-15,748,000-39,894,000-54,058,00036,581,000-13,506,000-6,309,000-1,342,0001,779,000
Net Income Margin-0.5%-0.43-0.43-0.43-0.48-0.35-0.31-0.19-0.09-0.17-0.13-0.21-0.35---------
Free Cashflow-29.1%-14,879,000-11,528,000-13,927,000-37,672,000-12,374,000-32,554,000-21,607,0003,170,000-13,978,0007,874,000-3,969,000-13,004,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.9%9409499579731,0021,0081,0311,0521,0501,0641,0441,0231,006995996780818307302228207
  Current Assets-1.0%395400401416444449471491486502491474469454453231263209201184177
    Cash Equivalents-14.2%93.0010995.0076.0012011311211610112312810610690.0027663.0072.0048.0049.0042.0039.00
  Inventory5.5%42.0040.0039.0040.0038.0034.0028.0025.0023.0020.0018.0015.0016.0020.0021.0028.0043.0013.0014.0013.0013.00
  Net PPE0.1%10310310398.0094.0087.0081.0075.0069.0061.0054.0043.0024.0023.0023.0023.0022.0020.0020.0020.0019.00
  Goodwill0%66.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.00----
Liabilities1.6%47947146846447246046945546346345943333833333313814511711443.0033.00
  Current Liabilities10.2%74.0067.0064.0062.0072.0061.0070.0056.0063.0063.0034933650.0047.0055.0051.0058.0033.0031.0027.0030.00
    LT Debt, Current-----------279279---------
Shareholder's Equity-3.3%462478489509530549562598587601584590667662662641673190188185174
  Retained Earnings-6.5%-599-562-531-499-464-432-405-359-365-343-349-332-310-299-283-243-189-226-212-206-205
  Additional Paid-In Capital2.0%1,0601,0391,0211,009997985972961952943933921977959944883862415399391378
Shares Outstanding0.8%49.0049.0048.0048.0048.0047.0047.0047.0046.0047.0046.0046.00---------
Float---3,445---2,067---3,792---1,634---2,679--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-30.6%-10,665-8,168-8,161-30,764-4,136-26,515-12,2069,774-4,65117,7907,3914,17810,604-9,570-10,923-13,099-4,191-2,9886,60220817,128
  Share Based Compensation23.9%12,98710,4849,87310,18411,6889,41110,5396,9237,2256,1897,9848,7488,7449,66010,89717,17612,4708,5478,2477,1296,668
Cashflow From Investing-186.7%-12,92114,89725,951-13,83216,65524,3919,630-5,897-8,872-26,063-2,034-21,263-3,459-181,562-20,66762849,812-4,074-599-1,713-17,752
Cashflow From Financing-2.2%7,3037,467-8801,1525294,2061061,4101,6173,86716,36217,4148,6595,821243,8424,220-22,0366,6663185,4071,974

GKOS Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS   
Net sales$ 314,711$ 282,862$ 294,011
Cost of sales75,57568,97966,627
Gross profit239,136213,883227,384
Operating expenses:   
Selling, general and administrative224,068192,925179,257
Research and development138,768123,271100,999
Acquired in-process research and development5,00010,00010,000
Litigation-related settlement (30,000)(30,000)
Total operating expenses367,836296,196260,256
Loss from operations(128,700)(82,313)(32,872)
Non-operating expense:   
Interest income9,1642,3751,288
Interest expense(13,633)(13,720)(13,372)
Other expense, net(558)(4,771)(4,311)
Total non-operating expense(5,027)(16,116)(16,395)
Loss before taxes(133,727)(98,429)(49,267)
Income tax provision934766326
Net loss$ (134,661)$ (99,195)$ (49,593)
Basic net loss per share (in dollar per share)$ (2.78)$ (2.09)$ (1.07)
Diluted net loss per share (in dollar per share)$ (2.78)$ (2.09)$ (1.07)
Weighted average shares outstanding used to compute basic net loss per share48,43347,44446,423
Weighted average shares outstanding used to compute diluted net loss per share48,43347,44446,423

GKOS Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 93,467$ 119,525
Short-term investments201,964233,170
Accounts receivable, net39,85036,073
Inventory41,98637,841
Prepaid expenses and other current assets18,19417,250
Total current assets395,461443,859
Restricted cash5,8567,078
Property and equipment, net103,21294,403
Operating lease right-of-use assets27,14625,826
Finance lease right-of-use asset44,18046,601
Intangible assets, net282,956307,869
Goodwill66,13466,134
Deposits and other assets15,46910,613
Total assets940,4141,002,383
Current liabilities:  
Accounts payable13,44014,403
Accrued liabilities60,57457,956
Total current liabilities74,01472,359
Convertible senior notes282,773281,400
Operating lease liability30,42728,905
Finance lease liability70,53872,172
Deferred tax liability, net7,1447,264
Other liabilities13,75210,278
Total liabilities478,648472,378
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and 2022
Common stock, $0.001 par value; 150,000 shares authorized; 49,148 and 47,782 shares issued and 49,120 and 47,754 shares outstanding as of December 31, 2023 and 2022, respectively4948
Additional paid-in capital1,059,751997,470
Accumulated other comprehensive income (loss)1,165(2,975)
Accumulated deficit(599,067)(464,406)
Less treasury stock (28 shares as of December 31, 2023 and 2022)(132)(132)
Total stockholders' equity461,766530,005
Total liabilities and stockholders' equity$ 940,414$ 1,002,383
GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.
 CEO
 WEBSITEglaukos.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES783

Glaukos Corp Frequently Asked Questions


What is the ticker symbol for Glaukos Corp? What does GKOS stand for in stocks?

GKOS is the stock ticker symbol of Glaukos Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Glaukos Corp (GKOS)?

As of Thu Apr 11 2024, market cap of Glaukos Corp is 4.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GKOS stock?

You can check GKOS's fair value in chart for subscribers.

What is the fair value of GKOS stock?

You can check GKOS's fair value in chart for subscribers. The fair value of Glaukos Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Glaukos Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GKOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Glaukos Corp a good stock to buy?

The fair value guage provides a quick view whether GKOS is over valued or under valued. Whether Glaukos Corp is cheap or expensive depends on the assumptions which impact Glaukos Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GKOS.

What is Glaukos Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 11 2024, GKOS's PE ratio (Price to Earnings) is -36.45 and Price to Sales (PS) ratio is 15.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GKOS PE ratio will change depending on the future growth rate expectations of investors.